Early detection of renal cell carcinoma: a novel cell-free DNA fragmentomics-based liquid biopsy assay

The cfDNA fragmentomics-based liquid biopsy provides a promising, noninvasive, cost-effective, and accurate approach for RCC detection and management, substantiating its potential as a complementary tool to conventional diagnostic techniques. Future research should explore integrating cfDNA fragmentomics with multi-omics approaches to enhance diagnostic precision and broaden clinical utility.